A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
A phase 3 trial of Pembrolizumab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study is a phase 3 interventional study registered as NCT05899049 by Merck Sharp & Dohme LLC, with 251 participants enrolled, started 2022-07-27 and due to reach its primary completion in 2026-02-04. Interventions recorded: Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab and Lenvatinib.
Similar pages
not linked directly; found by shared links- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Eisai, Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
- TrialSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Shares Eisai, Lenvatinib and the tag pipeline.